Basic Endocrine Autoantibodies Panel
EPIC Test Name: AUTO ANTIBODY PANEL
EPIC order code: LAB2189
This panel includes the following tests:
Adrenal Cortical Autoantibodies
Gastric Parietal Cell Autoantibodies
Islet Cell Autoantibodies
Thyroglobulin Autoantibodies (TGA)
Thyroperoxidase Autoantibodies (TPOA)
- 88350 (x 2)
Sample Volume: 2 mL
Minimum Volume: 0.5 mL (Repeat testing is not possible with this specimen volume.)
Storage: Centrifuge, separate and transfer the serum to a plastic vial. Ship specimens with a frozen cold pack for overnight delivery.
Stability (collection to time of analysis/testing):
- Refrigerated: 24 hours
- Frozen: 1 year
Diagnosis of an Autoimmune Endocrine Disorder: In the presence of clinical endocrine disease, an autoantibody directed against the affected gland indicates an autoimmune etiology for the glandular dysfunction.
Prediction of an Autoimmune Endocrine Disorder: Endocrine autoantibodies detected in an asymptomatic individual indicate an increased risk for the subsequent development of clinical endocrine disease. It is not recommended that asymptomatic, nondiabetic persons be screened for the presence of islet autoantibodies (e.g., ICA) unless these individuals are part of a research study. Positivity for thyroperoxidase autoantibodies (TPOA) and/or thyroglobulin autoantibodies (TGA) indicates an increased risk for the development of autoimmune thyroid disease. If TPOA or TGA are positive, yearly measurement of TSH anticipating the development of thyroid disease is a reasonable clinical management strategy. Positivity for gastric parietal cell autoantibodies (PCA) indicates an increased risk for autoimmune gastritis and the development of pernicious anemia. If PCA are positive, yearly measurements of ferritin and vitamin B12 are a reasonable clinical management strategy. Positivity for adrenal cortical autoantibodies (ACA) indicates an increased risk for the development of Addison disease. If ACA are positive, yearly measurements of supine renin and cortisol following cosyntropin injection anticipating the development of primary adrenal insufficiency is a reasonable clinical management strategy.
Indirect immunofluorescence, radioimmunoassay
1 - 10 Business Days